サイクリン依存性キナーゼ（CDK）4/6阻害剤の世界市場レポート 2025年

サイクリン依存性キナーゼ（CDK）4/6阻害剤の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR19.1％で300億6,000万米ドルに成長します。予測期間の成長は、適応症の拡大、新たなパイプライン分子、市場競争と価格ダイナミクス、個別化医療アプローチ、世界のヘルスケアインフラの改善などに起因すると考えられます。予測期間における主な動向としては、バイオマーカー同定の進展、経口CDK 4/6阻害剤の台頭、他のがん種におけるCDK 4/6阻害剤の出現、耐性メカニズムの克服への注力、新規CDK 4/6阻害剤を探索する臨床試験などが挙げられます。

乳がんの有病率の増加が予想されることから、サイクリン依存性キナーゼ（CDK）4/6阻害薬市場の成長が見込まれます。乳がんは乳房細胞から発生するため、CDK4/6阻害剤のような標的治療薬の需要が高まっており、特定のタイプの乳がんに対処し、急増する乳がんの有病率管理に貢献しています。2023年1月に米国がん学会が報告したように、乳がん症例は2021年の284,200人から2023年には300,590人に急増し、5.76％の大幅な増加を示しています。その結果、乳がんの有病率の上昇は、サイクリン依存性キナーゼ（CDK）4/6阻害薬市場の成長を推進する極めて重要な要因になると予測されます。

乳がん治療のための研究開発への投資の増加は、サイクリン依存性キナーゼ（CDK）4/6阻害剤市場を大きく押し上げると予想されます。乳がん治療における資金提供の増加は、CDK4/6阻害薬の技術革新と拡大を促進し、その有効性を高め、用途を広げることで、市場拡大を促進します。例えば、米国を拠点とする有名な乳がん団体であるSusan G. Komenは、2022年6月に、米国内の26の著名な学術医療機関における48の新規研究イニシアチブのスポンサーに2,170万米ドルを割り当てた。これらのイニシアチブは、特に進行性の乳がんと闘っている患者や再発・転移に直面している患者の転帰を改善することを目的としています。したがって、乳がん治療のための研究開発への投資の拡大は、サイクリン依存性キナーゼ（CDK）4/6阻害薬市場の成長を促進する重要な要因として浮上しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界サイクリン依存性キナーゼ（CDK）4/6阻害剤PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のサイクリン依存性キナーゼ（CDK）4/6阻害剤市場：成長率分析
• 世界のサイクリン依存性キナーゼ（CDK）4/6阻害剤市場の実績：規模と成長, 2019-2024
• 世界のサイクリン依存性キナーゼ（CDK）4/6阻害剤市場の予測：規模と成長, 2024-2029, 2034F
• 世界サイクリン依存性キナーゼ（CDK）4/6阻害剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のサイクリン依存性キナーゼ（CDK）4/6阻害剤市場薬の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• パルボシクリブ（イブランス）
• リボシクリブ（キスカリ）
• アベルマシクリブ（ヴェルゼニオ）
• 世界のサイクリン依存性キナーゼ（CDK）4/6阻害剤市場患者別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 閉経前
• 閉経後
• その他の患者
• 世界のサイクリン依存性キナーゼ（CDK）4/6阻害剤市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 調査室
• 小売薬局

第7章 地域別・国別分析

• 世界のサイクリン依存性キナーゼ（CDK）4/6阻害剤市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のサイクリン依存性キナーゼ（CDK）4/6阻害剤市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• サイクリン依存性キナーゼ（CDK）4/6阻害剤市場：競合情勢
• サイクリン依存性キナーゼ（CDK）4/6阻害剤市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Eli Lilly and Company
• Boehringer Ingelheim International GmbH
• Gilead Sciences Inc
• Incyte Corporation
• Jiangsu Hengrui Pharmaceuticals Co. Ltd.
• Dr. Reddy's Laboratories Ltd
• Piramal Group
• Hanmi Pharm Co. Ltd.
• Incepta Pharmaceuticals Ltd
• Beacon Pharmaceuticals PLC
• Bluepharma
• Astex Pharmaceuticals
• Arvinas Inc
• G1 Therapeutics Inc.
• Carisma Therapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• サイクリン依存性キナーゼ（CDK）4/6阻害剤市場2029：新たな機会を提供する国
• サイクリン依存性キナーゼ（CDK）4/6阻害剤市場2029：新たな機会を提供するセグメント
• サイクリン依存性キナーゼ（CDK）4/6阻害剤市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Cyclin-dependent kinase (CDK) 4/6 inhibitor drugs are a class of targeted therapy medications employed in the treatment of specific types of hormone receptor-positive, HER2-negative breast cancer. These drugs focus on inhibiting enzymes known as CDK4 and CDK6, disrupting signals that stimulate the proliferation of malignant cells.

The primary CDK 4/6 inhibitor drugs include palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio). Palbociclib, for instance, is a targeted therapy medication designed for treating hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer. It is often utilized in combination with endocrine therapy, offering an effective treatment option for patients with advanced or metastatic breast cancer. These drugs cater to various patient groups, such as premenopausal, postmenopausal, and others. The end users encompass hospitals, clinics, research laboratories, and retail pharmacies.

The cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market research report is one of a series of new reports from The Business Research Company that provides cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market statistics, including cyclin-dependent kinase (CDK) 4/6 inhibitor drugs industry global market size, regional shares, competitors with a cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market share, detailed cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market segments, market trends and opportunities, and any further data you may need to thrive in the cyclin-dependent kinase (CDK) 4/6 inhibitor drugs industry. This cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future- scenario of the industry.

The cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market size has grown exponentially in recent years. It will grow from $12.35 billion in 2024 to $14.95 billion in 2025 at a compound annual growth rate (CAGR) of 21.1%. The growth in the historic period can be attributed to increasing cancer incidence, clinical success stories, growing aging population, increased awareness, and early diagnosis.

The cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market size is expected to see rapid growth in the next few years. It will grow to $30.06 billion in 2029 at a compound annual growth rate (CAGR) of 19.1%. The growth in the forecast period can be attributed to expanding indications, emerging pipeline molecules, market competition and pricing dynamics, personalized medicine approaches, global healthcare infrastructure improvements. Major trends in the forecast period include advancements in biomarker identification, rise of oral CDK 4/6 inhibitors, emergence of CDK 4/6 inhibitors in other cancer types, focus on overcoming resistance mechanisms, clinical trials exploring novel CDK 4/6 inhibitors.

The anticipated increase in the prevalence of breast cancer is poised to drive the growth of the cyclin-dependent kinase (CDK) 4/6 inhibitor drug market. Breast cancer, originating in breast cells, prompts the demand for targeted therapies such as CDK4/6 inhibitors, addressing specific types of breast cancer and contributing to managing the escalating prevalence of the disease. As reported by the American Cancer Society in January 2023, breast cancer cases surged from 284,200 in 2021 to 300,590 in 2023, marking a significant increase of 5.76%. Consequently, the rising prevalence of breast cancer is forecasted to be a pivotal driver propelling growth within the cyclin-dependent kinase (CDK) 4/6 inhibitor drug market.

The augmented investment in research and development endeavors for breast cancer treatment is expected to significantly boost the cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market. The increased funding in breast cancer treatment facilitates the innovation and expansion of CDK4/6 inhibitor drugs, enhancing their efficacy and broadening their applications, thereby fostering market expansion. For instance, Susan G. Komen, a reputable US-based breast cancer organization, allocated $21.7 million in June 2022 to sponsor 48 novel research initiatives at 26 esteemed academic medical institutions across the United States. These initiatives aim to enhance patient outcomes, particularly for individuals grappling with aggressive forms of breast cancer or facing recurrence or metastasis. Hence, the amplified investment in research and development for breast cancer treatment emerges as a key factor driving the growth of the cyclin-dependent kinase (CDK) 4/6 inhibitor drug market.

Major companies in the cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market are concentrating on developing technologically advanced solutions, including AI-based tools to reduce toxicities in treatment and address various critical industry needs. These AI tools for hormonal breast cancer treatment aim to personalize therapies, minimize toxicities, predict adverse effects, and support timely interventions, ultimately enhancing the safety and effectiveness of treatments. For example, in May 2024, SOLTI, an innovative breast cancer research company based in Spain, launched an AI-based tool designed to reduce toxicities in the treatment of patients with hormonal breast cancer. This groundbreaking tool analyzes both cancerous and non-cancerous elements in breast tissue samples, allowing for more accurate predictions of treatment outcomes and helping to identify patients who may not need aggressive chemotherapy. By mitigating unnecessary side effects and enabling personalized treatment plans, the AI tool seeks to improve patient quality of life and enhance overall treatment efficacy. This advancement follows promising results from SOLTI's PATRICIA study, which emphasized the advantages of combining hormone therapy with targeted treatments for advanced ER+/HER2+ breast cancer.

In July 2022, Pfizer Inc., a renowned US-based pharmaceutical company specializing in CDK4/6 inhibitor drugs, embarked on a collaboration with Arvinas Inc., a prominent biopharmaceutical company also based in the United States. Their joint objective involves the development and commercialization of ARV-471, an investigative oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. This partnership is geared towards addressing the treatment needs of patients coping with locally advanced or metastatic breast cancer. Pfizer Inc. intends to synergize its expertise in CDK4/6 inhibitor drugs to maximize the therapeutic potential and effectiveness of ARV-471 in treating this challenging medical condition.

Major companies operating in the cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market report are Pfizer Inc., Merck & Co. Inc., Novartis AG, Bristol Myers Squibb Company, AstraZeneca PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Incyte Corporation, Jiangsu Hengrui Pharmaceuticals Co. Ltd., Dr. Reddy's Laboratories Ltd., Piramal Group, Hanmi Pharm Co. Ltd., Incepta Pharmaceuticals Ltd., Beacon Pharmaceuticals PLC, Bluepharma, Astex Pharmaceuticals, Arvinas Inc, G1 Therapeutics Inc., Carisma Therapeutics Inc., Beta Pharma Inc., Syros Pharmaceuticals Inc., Cyclacel Pharmaceuticals Inc., Onconova Therapeutics Inc., Context Therapeutics Inc., NanoDaru

North America was the largest region in the cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market in 2024. The regions covered in the cyclin-dependent kinase (cdk) 4/6 inhibitor drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the cyclin-dependent kinase (cdk) 4/6 inhibitor drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The cyclin-dependent kinase (CDK) 4/6 inhibitor drug market consists of sales of trilaciclib and ramiven drugs. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cyclin-dependent kinase (cdk) 4/6 inhibitor drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cyclin-dependent kinase (cdk) 4/6 inhibitor drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cyclin-dependent kinase (cdk) 4/6 inhibitor drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Palbociclib (Ibrance); Ribociclib (Kisqali); Abermaciclib (Verzenio)
• 3) By Patient: Pre-Menopausal; Post-Menopausal; Other Patients
• 3) By End-Users: Hospitals; Clinics; Research Laboratories; Retail Pharmacies
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Novartis AG; Bristol Myers Squibb Company; AstraZeneca PLC
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Characteristics

3. Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Trends And Strategies

4. Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Growth Rate Analysis
• 5.4. Global Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Total Addressable Market (TAM)

6. Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Segmentation

• 6.1. Global Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Palbociclib (Ibrance)
• Ribociclib (Kisqali)
• Abermaciclib (Verzenio)
• 6.2. Global Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pre-Menopausal
• Post-Menopausal
• Other Patients
• 6.3. Global Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Research Laboratories
• Retail Pharmacies

7. Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Regional And Country Analysis

• 7.1. Global Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 8.1. Asia-Pacific Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 9.1. China Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Overview
• 9.2. China Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 10.1. India Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 11.1. Japan Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Overview
• 11.2. Japan Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 12.1. Australia Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 13.1. Indonesia Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 14.1. South Korea Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Overview
• 14.2. South Korea Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 15.1. Western Europe Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Overview
• 15.2. Western Europe Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 16.1. UK Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 17.1. Germany Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 18.1. France Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 19.1. Italy Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 20.1. Spain Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 21.1. Eastern Europe Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Overview
• 21.2. Eastern Europe Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 22.1. Russia Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 23.1. North America Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Overview
• 23.2. North America Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 24.1. USA Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Overview
• 24.2. USA Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 25.1. Canada Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Overview
• 25.2. Canada Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 26.1. South America Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Overview
• 26.2. South America Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 27.1. Brazil Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 28.1. Middle East Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Overview
• 28.2. Middle East Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

• 29.1. Africa Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Overview
• 29.2. Africa Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By Patient, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Competitive Landscape And Company Profiles

• 30.1. Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Competitive Landscape
• 30.2. Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

31. Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Other Major And Innovative Companies

• 31.1. Eli Lilly and Company
• 31.2. Boehringer Ingelheim International GmbH
• 31.3. Gilead Sciences Inc
• 31.4. Incyte Corporation
• 31.5. Jiangsu Hengrui Pharmaceuticals Co. Ltd.
• 31.6. Dr. Reddy's Laboratories Ltd
• 31.7. Piramal Group
• 31.8. Hanmi Pharm Co. Ltd.
• 31.9. Incepta Pharmaceuticals Ltd
• 31.10. Beacon Pharmaceuticals PLC
• 31.11. Bluepharma
• 31.12. Astex Pharmaceuticals
• 31.13. Arvinas Inc
• 31.14. G1 Therapeutics Inc.
• 31.15. Carisma Therapeutics Inc.

32. Global Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

34. Recent Developments In The Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market

35. Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer